A5044318508- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Advanced Radiotherapy Techniques
- Pleural and Pulmonary Diseases
- Colorectal Cancer Treatments and Studies
- Colorectal and Anal Carcinomas
- Lymphoma Diagnosis and Treatment
- Occupational and environmental lung diseases
- Head and Neck Cancer Studies
- Cancer Research and Treatments
- Cancer therapeutics and mechanisms
- Medical Imaging and Pathology Studies
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- RNA modifications and cancer
- Advances in Oncology and Radiotherapy
- Cancer survivorship and care
- Multiple Myeloma Research and Treatments
- Genetic factors in colorectal cancer
- Tracheal and airway disorders
- Radiomics and Machine Learning in Medical Imaging
- Ethics in Clinical Research
National Cancer Institute
2014-2023
National Institutes of Health
2006-2022
Florida Memorial University
2021
Florida International University
2021
Specim (Finland)
2017
Advanced Cancer Therapeutics
2016
Leidos (United States)
2014-2016
Frederick National Laboratory for Cancer Research
2016
Center for Cancer Research
2015
Center for Drug Evaluation and Research
2010-2014
The Lung Master Protocol (Lung-MAP, S1400) is a groundbreaking clinical trial designed to advance the efficient development of targeted therapies for squamous cell carcinoma (SCC) lung. There are no approved specific advanced lung SCC, although Cancer Genome Atlas project and similar studies have detected significant number somatic gene mutations/amplifications in some which targetable by investigational agents. However, frequency these changes low (5%-20%), making recruitment study conduct...
Background: Small cell lung carcinoma (SCLC) is an aggressive, recalcitrant cancer, often metastatic at diagnosis and unresponsive to chemotherapy upon recurrence, thus it challenging treat. Methods: Sixty-three human SCLC lines three NSCLC were screened for response 103 US Food Drug Administration–approved oncology agents 423 investigational agents. The library was a diverse set of small molecules that included multiple compounds targeting the same molecular entity. in triplicate nine...
On August 26, 2011, the U.S. Food and Drug Administration (FDA) approved crizotinib (XALKORI Capsules, Pfizer Inc.) for treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive as detected by an FDA-approved test. The Vysis ALK Break-Apart FISH Probe Kit (Abbott Molecular, was concurrently. In two multicenter, single-arm trials, ALK-positive NSCLC previously treated one more systemic therapies received...
Standard treatment for resectable non-small cell lung cancer (NSCLC) includes anatomic resection with adequate lymph node dissection and adjuvant chemotherapy appropriate patients. Historically, many patients early-stage NSCLC have not received such treatment, which may affect the interpretation of results therapy trials.
Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer with distinctive regional racial prevalence. It associated Epstein-Barr virus infection has high propensity for distant metastases, while it very sensitive to radiation chemotherapy. A common feature virus-positive NPC the dense infiltration lymphocytes in tumor stroma positive programmed death-ligand 1 expression cells, making an attractive target immunotherapy, especially immune checkpoint inhibitors. As new immunotherapeutic...
Abstract BACKGROUND: Efatutazone (CS‐7017), a novel peroxisome proliferator‐activated receptor gamma (PPARγ) agonist, exerts anticancer activity in preclinical models. The authors conducted phase 1 study to determine the recommended 2 dose, safety, tolerability, and pharmacokinetics of efatutazone. METHODS: Patients with advanced solid malignancies no curative therapeutic options were enrolled receive given dose efatutazone, administered orally (PO) twice daily for 6 weeks, 3 + intercohort...
Recent advances have permitted successful therapeutic targeting of the immune system in head and neck squamous cell carcinoma (HNSCC). These new immunotherapeutic targets agents are being rapidly adopted by oncologic community hold considerable promise. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address issue how further investigate use immunotherapy patients with HNSCC. goals meeting were consider phase 2 or 3 trial designs primarily different patient...
Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell (NSCLC), immune checkpoint inhibitors (ICIs)- either as monotherapy or combination other ICIs chemotherapy-have demonstrated benefits first-line therapy advanced disease, the neoadjuvant adjuvant settings, well additional thoracic malignancies such small-cell (SCLC) mesothelioma. Challenging...
TPS9077 Background: ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a clinical trial platform of the National Institute that offers biomarker analysis for high-risk resected non-small cell lung cancer (NSCLC) to support randomized trials novel adjuvant therapies within Clinical Trials Network (NCTN). EA5142, nivolumab patients (pts) without EGFR / ALK alterations, has completed enrollment. Given survival benefit seen with 1st-line chemo-immunotherapy...
Tumor molecular profiling from patients experiencing exceptional responses to systemic therapy may provide insights into cancer biology and improve treatment tailoring. This pilot study evaluates the feasibility of identifying responders retrospectively, obtaining pre-exceptional response tumor tissues, analyzing them with state-of-the-art analysis tools identify potential explanations for responses.
Non-small-cell lung cancer (NSCLC) causes significant mortality each year. After successful resection of disease stage IB (>4 cm) to IIIA (per AJCC 7), adjuvant platinum-based chemotherapy improves median overall survival and is the standard care, but many patients still experience recurrence disease. An regimen with greater efficacy could substantially improve outcomes. Pembrolizumab, a programmed cell death-1 inhibitor, has become an important option in treatment metastatic NSCLC....
CyberKnife Frameless Image-Guided Stereotactic Radiosurgery with the Synchrony Motion Tracking Module is available for treatment of thoracic malignancies. Gold fiducials are used to mark tumor site and have traditionally been placed through computerized tomographic (CT) guidance. We describe first use video flexible bronchoscopy a modified transbronchial needle aspiration (TBNA) technique placement these fiducials. Fiducials were in 19-gauge 19/21-gauge needle. The fiducial-loaded was then...
On February 2, 2012, the National Cancer Institute (NCI) sponsored a 2-day workshop with NCI Thoracic Malignancies Steering Committee and Food Drug Administration to bring together leading academicians, clinicians, industry government representatives identify challenges potential solutions in clinical development of novel targeted therapies for lung cancer. Measures success are rapidly evolving from scientific regulatory perspective objectives this were achieve initial consensus on high...